■非伤寒沙门氏菌感染(NTS)是一种重要的食源性人畜共患病,健康和经济负担不足,低病死率。它在全球流行,在资源不足、卫生基础设施差的国家,负担更多。使用队列研究,我们确定了尼日利亚2020年NTS在人类中的成本效益。
■使用定制的基于Excel的成本效益分析工具,对尼日利亚的结构化(单一健康)和非结构化(针对NTS的间歇性干预)进行了评估。关于疾病负担的输入数据,成本监督,NTS的响应和控制来自经过验证的来源和公共卫生系统。
■非复杂和复杂病例分别为309,444(95%)和16,287(5%),方案费用总额为31,375,434.38美元。目前的非系统的偶发性干预费用为14,913,480.36美元,表明引入拟议干预的额外费用为16,461,954美元。干预措施将在一年内避免4036.98NTSDALY。非复杂NTS病例为60美元/人,复杂病例显著上升。有并发症和无并发症的NTS的累积成本远远超过了OneHealth干预计划的成本,增量成本效益比(ICER)为-221.30美元)。
■使用结构化的“一个健康”干预措施对尼日利亚的NTS具有成本效益,它对其他疾病有额外的缓解作用,成本更低,更有效,表明了优越的卫生系统方法。必须改进确定的限制,以优化相关利益,促进政策讨论和资源分配。
UNASSIGNED: Non-typhoidal Salmonella infection (NTS) is an important foodborne zoonosis with underappreciated health and economic burdens, and low case fatality. It has global prevalence, with more burdens in under-resourced countries with poor health infrastructures. Using a cohort study, we determined the cost-effectiveness of NTS in humans in Nigeria for the year 2020.
UNASSIGNED: Using a customized Excel-based cost-effectiveness analysis tool, structured (One Health) and unstructured (episodic intervention against NTS) in Nigeria were evaluated. Input data on the disease burdens, costs surveillance, response and control of NTS were obtained from validated sources and the public health system.
UNASSIGNED: The non-complicated and complicated cases were 309,444 (95%) and 16,287 (5%) respectively, and the overall programme cost was US$ 31,375,434.38. The current non-systematic episodic intervention costed US$ 14,913,480.36, indicating an additional US$ 16,461,954 to introduce the proposed intervention. The intervention will avert 4036.98 NTS DALYs in a single year. The non-complicated NTS case was US$ 60/person with significant rise in complicated cases. The cumulative costs of NTS with and without complications far outweighed the program cost for One Health intervention with an incremental cost-effectiveness ratio (ICER) of -US$ 221.30).
UNASSIGNED: Utilising structured One Health intervention is cost-effective against NTS in Nigeria, it carries additional mitigative benefits for other diseases and is less costly and more effective, indicative of a superior health system approach. Identified limitations must be improved to optimize benefits associated and facilitate policy discussions and resource allocation.